{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(12)"],"submitter":["Judd J"],"pubmed_abstract":["<i>KRAS</i> is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different <i>KRAS</i> mutations may represent a unique biologic context with different prognostic and therapeutic impact. We sought to characterize genomic landscapes of advanced, <i>KRAS</i>-mutated non-small cell lung cancer (NSCLC) in a large national cohort to help guide future therapeutic development.Molecular profiles of 17,095 NSCLC specimens were obtained using DNA next-generation sequencing of 592 genes (Caris Life Sciences) and classified on the basis of presence and subtype of <i>KRAS</i> mutations. Co-occurring genomic alterations, tumor mutational burden (TMB), and PD-L1 expression [22C3, tumor proportion score (TPS) score] were a"],"journal":["Molecular cancer therapeutics"],"pagination":["2577-2584"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9662933"],"repository":["biostudies-literature"],"pubmed_title":["Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer."],"pmcid":["PMC9662933"],"pubmed_authors":["Socinski MA","Kim C","Korn WM","Mamdani H","Nieva JJ","de Lima Lopes G","Liu SV","Borghaei H","Xiu J","Kim ES","Ikpeazu C","Naqash AR","Khan H","Wozniak AJ","Judd J","Abdel Karim N","Baca Y","Nagasaka M","VanderWalde AM","Pai SG","Spira AI","Raez LE"],"additional_accession":[]},"is_claimable":false,"name":"Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.","description":"<i>KRAS</i> is the most commonly mutated oncogene in NSCLC and development of direct KRAS inhibitors has renewed interest in this molecular variant. Different <i>KRAS</i> mutations may represent a unique biologic context with different prognostic and therapeutic impact. We sought to characterize genomic landscapes of advanced, <i>KRAS</i>-mutated non-small cell lung cancer (NSCLC) in a large national cohort to help guide future therapeutic development.Molecular profiles of 17,095 NSCLC specimens were obtained using DNA next-generation sequencing of 592 genes (Caris Life Sciences) and classified on the basis of presence and subtype of <i>KRAS</i> mutations. Co-occurring genomic alterations, tumor mutational burden (TMB), and PD-L1 expression [22C3, tumor proportion score (TPS) score] were a","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2025-07-11T03:03:58.994Z","creation":"2025-07-11T03:03:58.994Z"},"accession":"S-EPMC9662933","cross_references":{"pubmed":["34518295"],"doi":["10.1158/1535-7163.MCT-21-0201"]}}